Abstract
Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients and methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. Conclusion: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma.
| Original language | English |
|---|---|
| Pages (from-to) | 143-154 |
| Number of pages | 12 |
| Journal | Immunotherapy |
| Volume | 13 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2021 |
Keywords
- daratumumab
- multiple myeloma
- newly diagnosed
- standard of care
- transplant eligible
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Immunotherapy, Vol. 13, No. 2, 02.2021, p. 143-154.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma
T2 - Matching-adjusted indirect comparison
AU - Moreau, Philippe
AU - Hebraud, Benjamin
AU - Facon, Thierry
AU - Leleu, Xavier
AU - Hulin, Cyrille
AU - Hashim, Mahmoud
AU - Hu, Yannan
AU - Caillot, Denis
AU - Benboubker, Lofti
AU - Zweegman, Sonja
AU - Merz, Maximilian
AU - Weisel, Katja
AU - Salwender, Hans
AU - Mai, Elias K.
AU - Goldschmidt, Hartmut
AU - Bertsch, Uta
AU - Vanquickelberghe, Véronique
AU - Kampfenkel, Tobias
AU - Boer, Carla De
AU - Krotneva, Stanimira
AU - Proskorovsky, Irina
AU - He, Jianming
AU - Lam, Annette
AU - Lee, Charlene
AU - Cote, Sarah
AU - Sonneveld, Pieter
N1 - Funding Information: Editorial and medical writing support was provided by K Holmes of Ashfield Healthcare Communications, part of UDG Healthcare PLC, and J Bloom of Eloquent Scientific Solutions, and was funded by Janssen Global Services, LLC. Funding Information: The CASSIOPEIA study was supported by Janssen Research & Development in collaboration with the Intergroupe Francophone du Myélome (IFM) and Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON). The MM5 study was conducted by the German-speaking Myeloma Multicenter Study Group (GMMG) and supported by Celgene, Janssen-Cilag, Chugai and The Binding Site. Evidera, Inc., received funding from Janssen to participate in this study. P Moreau has served as a consultant for Ab-bVie, Amgen, Celgene, Janssen and Takeda and received honoraria from AbbVie, Amgen, Celgene, Janssen and Takeda. T Facon has served as an advisor for Amgen, Celgene, Janssen, Karyopharm, Oncopeptides, Roche, Sanofi and Takeda and participated in speakers’ bureaus for Celgene, Janssen and Takeda. X Leleu has received honoraria from AbbVie, Amgen, Bristol-Myers Squibb, Carsgen, Celgene, GSK, Incyte, Janssen, Karyopharm, Merck, Novartis, Oncopeptides, Sanofi and Takeda. C Hulin received honoraria from Amgen, Celgene, Janssen and Takeda. M Hashim and Y Hu are employees of Ingress Health. S Zweegman participated in advisory boards for Celgene, Janssen, Oncopeptides, Sanofi and Takeda and received research support from Celgene, Janssen and Takeda. M Merz acted as advisor for Amgen, Bristol-Myers Squibb and Takeda; received travel support from AbbVie, Amgen, Celgene and Takeda; and received research support outside of this study from Takeda. K Weisel received honoraria and is advisory board member for Amgen, Bristol-Myers Squibb, Celgene, GSK, Janssen, Karyopharm, Sanofi and Takeda and research funding (to the institution) from Amgen, Celgene, Janssen and Sanofi. H Salwender received honoraria and travel expenses from Abb-Vie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Oncopeptides, Sanofi and Takeda. EK Mai received honoraria from Celgene, Janssen and Takeda; had a consulting or advisory role with Celgene, Janssen and Takeda; received research funding from Takeda; and received travel accommodations and expenses from Celgene, Janssen, Mundipharma and Takeda. H Goldschmidt received grants and/or provision of Investigational Medicinal Product (IMP) from Amgen, Bristol-Myers Squibb, Celgene, Chugai, Dietmar Hopp Stiftung, Janssen, Johns Hopkins University and Sanofi; research support (institutions) from Amgen, Bristol-Myers Squibb, Celgene, Chugai, Janssen, Molecular Partners, MSD, Mundipharma, Novartis, Sanofi and Takeda; advisory board honoraria from Adaptive Biotechnology, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Sanofi and Takeda; and speakers’ bureau honoraria from ArtTempi, Bristol-Myers Squibb, Celgene, Chugai, Janssen, Novartis and Sanofi. U Bertsch has received travel, accommodations and expenses from Sanofi. V Vanquickelberghe, T Kampfenkel, C de Boer, J He, A Lam, C Lee and S Cote are employees of Janssen. S Krotneva and I Proskorovsky are employees of Evidera, Inc. P Sonneveld received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Karyopharm and Takeda and research funding from Amgen, Celgene, Janssen, Karyopharm, SkylineDx and Takeda. B Hebraud, D Caillot and L Benboubker have no conflicts of interest to disclose. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: © 2021 Future Medicine Ltd. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/2
Y1 - 2021/2
N2 - Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients and methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. Conclusion: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma.
AB - Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients and methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. Conclusion: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma.
KW - daratumumab
KW - multiple myeloma
KW - newly diagnosed
KW - standard of care
KW - transplant eligible
UR - http://www.scopus.com/inward/record.url?scp=85098178835&partnerID=8YFLogxK
U2 - https://doi.org/10.2217/imt-2020-0266
DO - https://doi.org/10.2217/imt-2020-0266
M3 - Article
C2 - 33228440
SN - 1750-743X
VL - 13
SP - 143
EP - 154
JO - Immunotherapy
JF - Immunotherapy
IS - 2
ER -